The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC

British Journal of Cancer

Volumn 112, Issue 1, 2015, Pages 122-130

  Voorneveld, P W ^a   Kodach, L L ^a   Jacobs, R J ^a   Van Noesel, C J M ^b   Peppelenbosch, M P ^c   Korkmaz, K S ^a   Molendijk, I ^a   Dekker, E ^b   Morreau, H ^a   Van Pelt, G W ^a   Tollenaar, R A E M ^a   Mesker, W ^a   Hawinkels, L J A C ^a   Paauwe, M ^a   Verspaget, H W ^a   Geraets, D T ^d   Hommes, D W ^a,e   Offerhaus, G J A ^f   Van Den Brink, G R ^a,b   Ten Dijke, P ^a   Hardwick, J C H ^a   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d DDL DIAGNOSTIC LABORATORY   (Netherlands)

^e UCLA MEDICAL CENTER   (United States)

^f Department of Surgery Leiden University Medical Center ^*  (Netherlands)

Author keywords

5 FU; ALK3 inhibitor; beta catenin; chemotherapy; colon cancer; invasive front; metastasis; p53

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN; FLUOROURACIL; PROTEIN P53; SMAD4 PROTEIN; CTNNB1 PROTEIN, HUMAN; SMAD4 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CHEMOSENSITIVITY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MTT ASSAY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STAINING; TUMOR INVASION; WNT SIGNALING PATHWAY; COLORECTAL TUMOR; GENETIC TRANSFECTION; GENETICS; HCT116 CELL LINE; HEK293 CELL LINE; HT 29 CELL LINE; METABOLISM; PATHOLOGY;

BETA CATENIN; BONE MORPHOGENETIC PROTEINS; COLORECTAL NEOPLASMS; HCT116 CELLS; HEK293 CELLS; HT29 CELLS; HUMANS; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; WNT SIGNALING PATHWAY;

EID: 84920675634     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.560     Document Type: Article

References (42)

1. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, Parenti AR, Rosato A, Bicciato S, Balmain A, Piccolo S (2009) A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137(1): 87-98.
2. Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin JP, Hemminki A, Schwartz Jr S, Aaltonen LA, Arango D (2005) SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 11(7): 2606-2611.
3. Alhopuro P, Alazzouzi H, Sammalkorpi H, Davalos V, Salovaara R, Hemminki A, Jarvinen H, Mecklin JP, Schwartz Jr S, Aaltonen LA, Arango D (2005) SMAD4 levels and response to 5-fluorouracil in colorectal cancer. Clin Cancer Res 11(17): 6311-6316.
4. Auclair BA, Benoit YD, Rivard N, Mishina Y, Perreault N (2007) Bone morphogenetic protein signaling is essential for terminal differentiation of the intestinal secretory cell lineage. Gastroenterology 133(3): 887-896.
5. Beck SE, Jung BH, Fiorino A, Gomez J, Rosario ED, Cabrera BL, Huang SC, Chow JY, Carethers JM (2006) Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol 291(1): G135-G145.
6. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, Knuechel R, Kirchner T (2001) Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 98(18): 10356-10361.
7. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104(3): 263-269.
8. Carlotti F, Bazuine M, Kekarainen T, Seppen J, Pognonec P, Maassen JA, Hoeben RC (2004) Lentiviral vectors efficiently transduce quiescent mature 3T3-L1 adipocytes. Mol Ther 9(2): 209-217.
9. Cho KR, Vogelstein B (1992) Suppressor gene alterations in the colorectal adenoma-carcinoma sequence. J Cell Biochem Suppl 16G: 137-141.
10. Curtin K, Slattery ML, Holubkov R, Edwards S, Holden JA, Samowitz WS (2004) p53 alterations in colon tumors: a comparison of SSCP/sequencing and immunohistochemistry. Appl Immunohistochem Mol Morphol 12(4): 380-386.
11. Dennler S, Itoh S, Vivien D, Ten DP, Huet S, Gauthier JM (1998) Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17(11): 3091-3100.
12. Fodde R, Brabletz T (2007) Wnt/β-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 19(2): 150-158.
13. Freeman TJ, Smith JJ, Chen X, Washington MK, Roland JT, Means AL, Eschrich SA, Yeatman TJ, Deane NG, Beauchamp RD (2012) Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of beta-catenin. Gastroenterology 142(3): 562-571.
14. Haramis AP, Begthel H, van den Born M, van EJ, Jonkheer S, Offerhaus GJ, Clevers H (2004) De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science 303(5664): 1684-1686.
15. Hardwick JC, van den Brink GR, Bleuming SA, Ballester I, Van Den Brande JM, Keller JJ, Offerhaus GJ, van Deventer SJ, Peppelenbosch MP (2004) Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 126(1): 111-121.
16. Hawkins DS, Demers GW, Galloway DA (1996) Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56(4): 892-898.
17. He XC, Zhang J, Tong WG, Tawfik O, Ross J, Scoville DH, Tian Q, Zeng X, He X, Wiedemann LM, Mishina Y, Li L (2004) BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat Genet 36(10): 1117-1121.
18. Karagiannis GS, Berk A, Dimitromanolakis A, Diamandis EP (2013) Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1. Mol Oncol 7(4): 826-839.
19. Kim NH, Kim HS, Kim NG, Lee I, Choi HS, Li XY, Kang SE, Cha SY, Ryu JK, Na JM, Park C, Kim K, Lee S, Gumbiner BM, Yook JI, Weiss SJ (2011) p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal 4(197): ra71.
20. Kodach LL, Wiercinska E, de Miranda NF, Bleuming SA, Musler AR, PeppelenboschMP, Dekker E, van den Brink GR, van Noesel CJ, Morreau H, Hommes DW, Ten DP, Offerhaus GJ, Hardwick JC (2008) The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. Gastroenterology 134(5): 1332-1341.
21. Korchynskyi O, Ten DP (2002) Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem 277(7): 4883-4891.
22. Kosinski C, Li VS, Chan AS, Zhang J, Ho C, Tsui WY, Chan TL, Mifflin RC, Powell DW, Yuen ST, Leung SY, Chen X (2007) Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci USA 104(39): 15418-15423.
23. Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L, Gulotta G, Dieli F, de Maria R, Stassi G (2011) Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 140(1): 297-309.
24. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266(5186): 807-810.
25. McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, Cabrera L, Keller E, McCauley L, Cho KR, Buckanovich RJ (2011) Human ovarian carcinomaassociated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest 121(8): 3206-3219.
26. Mesker WE, Liefers GJ, Junggeburt JM, van Pelt GW, Alberici P, Kuppen PJ, Miranda NF, van Leeuwen KA, Morreau H, Szuhai K, Tollenaar RA, Tanke HJ (2009) Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell Oncol 31(3): 169-178.
27. Papageorgis P, Cheng K, Ozturk S, Gong Y, Lambert AW, Abdolmaleky HM, Zhou JR, Thiagalingam S (2011) Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res 71(3): 998-1008.
28. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F, Vescovi AL (2006) Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444(7120): 761-765.
29. Radtke F, Clevers H (2005) Self-renewal and cancer of the gut: two sides of a coin. Science 307(5717): 1904-1909.
30. Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita H, Ten DP, Heldin CH, Miyazono K (1995) Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sci USA 92(17): 7632-7636.
31. Sinnberg T, Menzel M, Ewerth D, Sauer B, Schwarz M, Schaller M, Garbe C, Schittek B (2011) beta-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance. PLoS One 6(8): e23429.
32. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314(5797): 268-274.
33. Sneddon JB, Zhen HH, Montgomery K, van de Rijn M, Tward AD, West R, Gladstone H, Chang HY, Morganroth GS, Oro AE, Brown PO (2006) Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci USA 103(40): 14842-14847.
34. Sur S, Pagliarini R, Bunz F, Rago C, Diaz Jr LA, Kinzler KW, Vogelstein B, Papadopoulos N (2009) A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 106(10): 3964-3969.
35. Tago K, Nakamura T, Nishita M, Hyodo J, Nagai S, Murata Y, Adachi S, Ohwada S, Morishita Y, Shibuya H, Akiyama T (2000) Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein. Genes Dev 14(14): 1741-1749.
36. van VW, Le NH, Helvensteijn W, Blonden L, Theeuwes M, Bakker ER, Franken PF, van GL, Meijlink F, van der Valk MA, Kuipers EJ, Fodde R, Smits R (2011) beta-catenin tyrosine 654 phosphorylation increases Wnt signalling and intestinal tumorigenesis. Gut 60(9): 1204-1212.
37. Vermeulen L, De Sousa E, Melo F, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G, Medema JP (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12(5): 468-476.
38. Voorneveld PW, Kodach LL, Jacobs RJ, Liv N, Zonnevylle AC, Hoogenboom JP, Biemond I, Verspaget HW, Hommes DW, de Rooij K, van Noesel CJ, Morreau H, van Wezel T, Offerhaus GJ, van den Brink GR, Peppelenbosch MP, Ten DP, Hardwick JC (2014) Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK. Gastroenterology 1471: 196-208.e13.
39. Voorneveld PW, Stache V, Jacobs RJ, Smolders E, Sitters AI, Liesker A, Korkmaz S, Lam SM, de Miranda NF, Morreau H, Kodach LL, Hardwick JC (2013) Reduced expression of bone morphogenetic protein receptor IA in pancreatic cancer is associated with a poor prognosis. Br J Cancer 109(7): 1805-1812.
40. Wakefield LM, Hill CS (2013) Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat Rev Cancer 13(5): 328-341.
41. Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih I, Kurman RJ (2011) Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 24(9): 1248-1253.
42. Zhou S, Buckhaults P, Zawel L, Bunz F, Riggins G, Dai JL, Kern SE, Kinzler KW, Vogelstein B (1998) Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells. Proc Natl Acad Sci USA 95(5): 2412-2416.